REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay w ...

Nautilus Biotechnology (NAUT) FY Conference June 10, 2025 02:00 PM ET Speaker0 You do, okay. Speaker1 question, I'll answer that. Speaker0 Oh, you're right. It does have that. Great. Good afternoon, everyone. I'm Matt Sykes, Life Science Tools and Diagnostics Analyst at Goldman Sachs. I have the pleasure of welcoming Anna Mari from Nautilus Biotechnologies. Thank you, Anna, for being here. Appreciate it. Maybe just starting off with big picture, can you give us kind of a brief overview of the proteomics mar ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $4.2 million, a 37% increase from $3.1 million in Q1 2024, primarily driven by higher instrument consumable and service revenue [23] - Gross profit for Q1 2025 was $2.1 million, representing a gross margin of 49%, compared to $1.4 million and 44% in Q1 2024 [26] - Net loss for Q1 2025 was $19.9 million, compared to $20.7 million in Q1 2024 [28] - Free cash flow loss was approximately $12.1 million for Q1 2025, with expectations of a full-year loss in the range of $40 million to $45 million [28][29] Business Line Data and Key Metrics Changes - Product revenue for Q1 2025 was $2.9 million, including $5,000 from related party revenue, consisting of sales of proteograph instruments and consumable kits [23] - Service revenue for Q1 2025 was $1.2 million, including $47,000 from related party revenue, primarily from STACK service projects [25] - Other revenue was $60,000 for Q1 2025, consisting of lease and shipping revenue [26] Market Data and Key Metrics Changes - Approximately 30% of total revenue comes from academic and government entities, with expectations of weakening in these segments for 2025 [31][44] - The company has seen a stabilization in revenue and instrument placement between academic, government, and biopharma sectors in Q1 2025 [44] Company Strategy and Development Direction - The company aims to focus on four key growth drivers in 2025: expanding the user base, driving larger cohort studies, continuing product innovation, and enabling customers to generate actionable biological insights [35] - The company is making concentrated investments in R&D to execute its product roadmap while continuing its share repurchase program [9][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term vision despite near-term macroeconomic volatility, including tariffs and government funding challenges [6][8] - The company reiterated its full-year 2025 revenue guidance of $17 million to $18 million, representing 24% year-over-year growth at the midpoint [8][30] - Management acknowledged potential impacts from tariffs and government funding uncertainties but remains optimistic about the demand for proteomics technology [31][32] Other Important Information - The company ended Q1 2025 with approximately $285 million in cash, cash equivalents, and investments, which is seen as a key differentiator in the current environment [9][29] - The company has initiated a Strategic Instrument Placement Program (SIPP) to help customers with capital constraints, allowing them to access instruments through upfront purchases of consumable kits [18] Q&A Session Summary Question: Can you walk us through the magnitude of the Discovery Life Sciences project? - Management confirmed it is a significant 10,000 sample study aimed at understanding potential biomarker signatures, expected to take 12 to 18 months [37][38] Question: What are the updated expectations for U.S. academic and government customers? - Management indicated that academic and government revenue is expected to decline, but Q1 showed stabilization in revenue and instrument placements [44][46]

Seer (SEER) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the SEER First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you'll need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please pr ...

Core Insights - Seer, Inc. reported a revenue growth of 37% in Q1 2025, reaching $4.2 million compared to $3.1 million in the same period last year, driven by increased product sales and service revenue [4][6] - The company shipped as many Proteograph instruments in Q1 2025 as it did in all of 2024, indicating strong momentum in product demand [3][9] - Seer expects full-year 2025 revenue to be between $17 million and $18 million, representing a 24% growth at the midpoint compared to 2024 [7] Financial Performance - Product revenue for Q1 2025 was $2.9 million, while service revenue was $1.2 million, contributing to the overall revenue increase [4][13] - Gross profit for the quarter was $2.1 million, with a gross margin of 49% [5][13] - Operating expenses decreased by 14% to $22.8 million, primarily due to lower stock-based compensation and laboratory expenses [5][13] Net Loss and Cash Position - The net loss for Q1 2025 was $19.9 million, slightly improved from a net loss of $20.7 million in the same period last year [6][14] - As of March 31, 2025, the company had approximately $285 million in cash, cash equivalents, and investments [6][9] Strategic Developments - Seer secured a significant contract with a new customer for a 10,000-sample study in collaboration with Discovery Life Sciences [9] - The company is accelerating third-party validation of its platform through an increasing number of customer publications and webinars [9] Market Context - The CEO highlighted the ongoing macroeconomic headwinds affecting the life sciences industry but maintained a long-term vision for the company [3]